Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Although rectal neuroendocrine tumors (NETs) with L-cell phenotype and small tumor size generally had better clinical behavior, the new 2019 WHO classification classified all rectal NETs are malignant without considering L-cell phenotype and small tumor size. Therefore, identifying biomarkers of rectal NETs is important to stratify the clinical behavior of rectal NETs.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Kim J
Authors: Kim J, Kim J, Oh E, Yang D, Hong S,
Keywords: Rectal neuroendocrine tumor, Chromogranin, Immunohistochemistry, Prognosis,
Introduction: Knowledge about gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) is scarce given their low incidence rates and aggressive clinical behavior
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Dasari A, Mehta K, Sorbye H, Yao J,
Keywords: Grade 3, NE carcinoma,
#1477 Neuroendocrine Tumors of the Biliary Tract: A Retrospective, Observational Multicenter Study
Introduction: Neuroendocrine tumors of the biliary tract (BTNETs) constitute a heterogeneous group of neoplasms. Because of their rarity, the clinical behavior is unclear.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Brizzi M, Massironi S, Pusceddu S, De Nigris B, Birocco N,
Keywords: Biliary tract NET,
Introduction: LCNEC is a rare non-small cell lung cancer subtype and clinical behavior is unclear.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Derks J
Authors: Derks J, Hendriks L, Damhuis R, Speel E, Dingemans A,
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The “crosstalk” of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Freitag H, Briest F, Christen F, Grass I, Lewens F,
Keywords: dual inhibition, PI3K, mTOR, PKI-587,RAD001, signaling,